[登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > [Pyr1]-Apelin-13
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
[Pyr1]-Apelin-13
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
[Pyr1]-Apelin-13图片
CAS NO:217082-60-5
包装与价格：
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
[Pyr1]-Apelin-13 是一种高效的选择性内源性 apelin 受体 (APJ) 激动剂。
Cas No.217082-60-5
别名人牛吡啶APELIN-13,[pGlu1]-Apelin-13
分子式C69H108N22O16S
分子量1533.81
溶解度Soluble to 1 mg/ml in sterile water
储存条件Desiccate at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

[Pyr1]-Apelin-13 is a highly potent, selective endogenous apelin receptor (APJ) agonist.

[Pyr1]-apelin-13 encapsulation in lipoPEG particles (lipoPEG-PA13) results in sustained and extended drug release under physiological conditions[1].

[Pyr1]-apelin-13 nanocarriers in a mouse model of pressure-overload induced heart failure demonstrate a sustainable long-term effect of [Pyr1]-apelin-13 in preventing cardiac dysfunction[1]. [Pyr1] apelin-13 (1, 5 μg) improves locomotor activity and reduces pain symptoms, cavity size and caspase-3 levels in rats. [Pyr1] apelin-13 (1, 5 μg) significantly increases thermal paw withdrawal latency. [Pyr1] apelin-13 in 5 μg dose also produces significant attenuation in paw withdrawal threshold compared to SCI animals from the second week post SCI[2].

References:
[1]. Serpooshan V, et al. [Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction. Biomaterials. 2015 Jan;37:289-98.
[2]. Hajimashhadi Z, et al. Chronic administration of [Pyr1] apelin-13 attenuates neuropathic pain after compression spinal cord injury in rats. Neuropeptides. 2017 Feb;61:15-22.